{"id":846847,"date":"2026-11-09T16:38:03","date_gmt":"2026-11-09T16:38:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=846847"},"modified":"2026-11-09T16:38:03","modified_gmt":"2026-11-09T16:38:03","slug":"crohns-disease-clinical-trial-pipeline-expands-as-90-companies-race-to-redefine-crohns-disease-treatment-landscape-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-clinical-trial-pipeline-expands-as-90-companies-race-to-redefine-crohns-disease-treatment-landscape-delveinsight_846847.html","title":{"rendered":"Crohn\u2019s Disease Clinical Trial Pipeline Expands as 90+ Companies Race to Redefine Crohn\u2019s Disease Treatment Landscape | DelveInsight"},"content":{"rendered":"<div style=\"font-style:italic; padding:8px 0px;\">The Crohn\u2019s Disease Clinical Trial analysis report delivers important insights into ongoing research on 90+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, US) November 09, 2026-<\/strong> DelveInsight&rsquo;s, &ldquo;<strong>Crohn&rsquo;s Disease Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn&rsquo;s Disease pipeline landscape. It covers the Crohn&#8217;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn&#8217;s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Stay ahead in understanding the Crohn&#8217;s Disease Treatment Landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Crohn&#8217;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On November 05, 2026 &ndash; Shattuck Labs<\/em><\/strong> announced the initiation of the Phase IIb RECEPTIVE-CD1 clinical trial evaluating SL-325, an investigational DR3-blocking antibody, in patients with moderately to severely active Crohn&#8217;s disease. The trial will assess the drug&#8217;s efficacy and safety, with initial induction data expected in the first half of 2028.<\/li>\n<li><strong><em>On October 23, 2026 &ndash; AbbVie<\/em><\/strong> received U.S. FDA approval for a subcutaneous induction regimen of SKYRIZI&reg; (risankizumab) for adults with moderately to severely active Crohn&#8217;s disease, providing patients with an additional at-home treatment administration option through an on-body injector.<\/li>\n<li><strong><em>On October 20, 2026 &ndash; Sanofi and Teva Pharmaceuticals<\/em><\/strong> announced positive long-term Phase IIb RELIEVE UCCD study results for duvakitug, demonstrating sustained clinical remission, clinical response, and endoscopic improvements through Week 44 in patients with Crohn&#8217;s disease.<\/li>\n<li><strong><em>On October 15, 2026 &ndash; Eli Lilly and Company<\/em><\/strong> reported new clinical data showing that 20.4% of patients with Crohn&#8217;s disease treated with Omvoh&reg; (mirikizumab) achieved corticosteroid-free deep remission at one year in the Phase III VIVID-1 study<\/li>\n<li>DelveInsight&rsquo;s <strong>Crohn&#8217;s Disease pipeline report<\/strong> depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn&#8217;s Disease treatment.<\/li>\n<li>The leading Crohn&#8217;s Disease companies such as <strong><em>Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo<\/em><\/strong> and others.<\/li>\n<li>Promising Crohn&rsquo;s Disease Pipeline Therapies such as <strong><em>Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Gain in-depth knowledge of key Crohn&#8217;s Disease clinical trials, emerging drugs, and market opportunities @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&rsquo;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Crohn&rsquo;s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn&rsquo;s disease has the potential to progress extensively. The inflammation observed in the digestive tract is followed by abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn&rsquo;s disease in people can be both painful and weakening, sometimes leading to life-threatening complications. The inflammation caused in the intestine can be skipped in between the patches of diseased intestine. The signs and symptoms observed in patients suffering from Crohn&rsquo;s disease tends to vary and can change over a period of time.<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Guselkumab: Janssen<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Guselkumab is a human immunoglobulin G1 lambda (IgG1&lambda;) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>RHB-104: RedHill Biopharma<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing Prevalence of Inflammatory Bowel Disease<\/li>\n<li>Development of New and Effective Therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Limited awareness and education<\/li>\n<li>Failures and discontinuation of emerging therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>The Crohn&rsquo;s Disease Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Crohn&rsquo;s Disease with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn&rsquo;s Disease Treatment.<\/li>\n<li>Crohn&rsquo;s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Crohn&rsquo;s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn&rsquo;s Disease market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Uncover critical updates on therapeutic innovations and their potential impact on patients @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>See the latest progress in drug development and clinical research @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Crohn&#8217;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Crohn&#8217;s Disease Companies- <strong><em>Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo<\/em><\/strong> and others.<\/li>\n<li>Crohn&rsquo;s Disease Pipeline Therapies- <strong><em>Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13,<\/em><\/strong> and others.<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Access the Full Crohn&#8217;s Disease Pipeline Analysis Today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Crohn&#8217;s Disease Executive Summary<\/li>\n<li>Crohn&rsquo;s Disease: Overview<\/li>\n<li>Crohn&#8217;s Disease Pipeline Therapeutics<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment<\/li>\n<li>Crohn&rsquo;s Disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Ozanimod: Bristol-Myers Squibb<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>CBP-307: Suzhou Connect Biopharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>IMU-856: Immunic<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Crohn&rsquo;s Disease Key Companies<\/li>\n<li>Crohn&rsquo;s Disease Key Products<\/li>\n<li>Crohn&rsquo;s Disease Unmet Needs<\/li>\n<li>Crohn&rsquo;s Disease Market Drivers and Barriers<\/li>\n<li>Crohn&rsquo;s Disease Future Perspectives and Conclusion<\/li>\n<li>Crohn&rsquo;s Disease Analyst Views<\/li>\n<li>Crohn&rsquo;s Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crohns-disease-clinical-trial-pipeline-expands-as-90-companies-race-to-redefine-crohns-disease-treatment-landscape-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crohns-disease-clinical-trial-pipeline-expands-as-90-companies-race-to-redefine-crohns-disease-treatment-landscape-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Crohn\u2019s Disease Clinical Trial analysis report delivers important insights into ongoing research on 90+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) November 09, 2026- DelveInsight&rsquo;s, &ldquo;Crohn&rsquo;s Disease Pipeline Insight 2026&rdquo; report provides comprehensive insights about &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-clinical-trial-pipeline-expands-as-90-companies-race-to-redefine-crohns-disease-treatment-landscape-delveinsight_846847.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-846847","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/846847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=846847"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/846847\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=846847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=846847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=846847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}